CN102884084B - 抗her2抗体及组合物 - Google Patents

抗her2抗体及组合物 Download PDF

Info

Publication number
CN102884084B
CN102884084B CN201180022307.6A CN201180022307A CN102884084B CN 102884084 B CN102884084 B CN 102884084B CN 201180022307 A CN201180022307 A CN 201180022307A CN 102884084 B CN102884084 B CN 102884084B
Authority
CN
China
Prior art keywords
antibody
sequence
heavy chain
light
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180022307.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102884084A (zh
Inventor
M·W·佩德森
A·詹森
P-J·梅杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of CN102884084A publication Critical patent/CN102884084A/zh
Application granted granted Critical
Publication of CN102884084B publication Critical patent/CN102884084B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180022307.6A 2010-03-04 2011-03-03 抗her2抗体及组合物 Expired - Fee Related CN102884084B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31055210P 2010-03-04 2010-03-04
DKPA201070085 2010-03-04
DKPA201070085 2010-03-04
US61/310,552 2010-03-04
US35413310P 2010-06-11 2010-06-11
US61/354,133 2010-06-11
US201061428014P 2010-12-29 2010-12-29
US61/428,014 2010-12-29
PCT/IB2011/050903 WO2011107957A1 (en) 2010-03-04 2011-03-03 Anti-her2 antibodies and compositions

Publications (2)

Publication Number Publication Date
CN102884084A CN102884084A (zh) 2013-01-16
CN102884084B true CN102884084B (zh) 2016-12-07

Family

ID=44541704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180022307.6A Expired - Fee Related CN102884084B (zh) 2010-03-04 2011-03-03 抗her2抗体及组合物

Country Status (5)

Country Link
EP (1) EP2542589A4 (hr)
JP (1) JP6039428B2 (hr)
CN (1) CN102884084B (hr)
TW (1) TW201141519A (hr)
WO (1) WO2011107957A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883149B2 (en) 2008-09-15 2014-11-11 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CA2816520C (en) 2010-11-01 2017-11-21 Symphogen A/S Anti-her3 antibodies and compositions
EP2710038B1 (en) 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
CN104428318B (zh) 2012-05-02 2018-09-25 西福根有限公司 人源化泛her抗体组合物
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
RU2656161C1 (ru) * 2013-11-19 2018-05-31 Ремеджен, Лтд. Анти-неr2 антитело и его конъюгат
CN104974261B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗her2/ps双特异性抗体、其制备方法和应用
BR112017011170A2 (pt) * 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
CN106831987B (zh) * 2015-12-04 2020-01-21 浙江大学 一种抗人her2抗体及其编码基因和应用
CN109154600A (zh) * 2016-06-16 2019-01-04 豪夫迈·罗氏有限公司 用于确定cdc诱导抗体的测定法和方法
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
CN107137424A (zh) * 2017-05-15 2017-09-08 广州领晟医疗科技有限公司 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法
WO2019173911A1 (en) * 2018-03-13 2019-09-19 Zymeworks Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
CN109134656A (zh) * 2018-09-12 2019-01-04 四川妙和生物科技有限公司 一种抗her2多克隆抗体
WO2020191434A1 (en) * 2019-03-22 2020-10-01 Olivia Newton-John Cancer Research Institute Anti-her2 binding molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055367A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California INTERNALIZING ErbB2 ANTIBODIES
WO2006087637A2 (en) * 2005-02-21 2006-08-24 Hellenic Pasteur Institute Anti her2/neu antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
JP5719298B2 (ja) * 2008-08-29 2015-05-13 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組換え抗上皮増殖因子受容体抗体組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055367A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California INTERNALIZING ErbB2 ANTIBODIES
WO2006087637A2 (en) * 2005-02-21 2006-08-24 Hellenic Pasteur Institute Anti her2/neu antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells;Rita Nahta，et al.;《Cancer Research》;20040401;第64卷(第7期);摘要和第2343页左栏第2-3段，第2344页右栏最后1段 *

Also Published As

Publication number Publication date
EP2542589A4 (en) 2013-08-07
TW201141519A (en) 2011-12-01
EP2542589A1 (en) 2013-01-09
JP6039428B2 (ja) 2016-12-07
WO2011107957A1 (en) 2011-09-09
JP2013520984A (ja) 2013-06-10
CN102884084A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
CN102884084B (zh) 抗her2抗体及组合物
US10221246B2 (en) Pan-HER antibody composition
US9217039B2 (en) Anti-HER3 antibodies and compositions
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
CN104093743B (zh) 特异于her3的结合分子及其用途
US8609095B2 (en) Anti-HER2 antibodies and compositions
CN105884900A (zh) 单特异性和双特异性抗igf-1r和抗erbb3抗体
CN107708666A (zh) 治疗癌症的联合疗法
JP2020515594A (ja) Ｅｒｂｂ−２、ｅｒｂｂ−２／ｅｒｂｂ−３陽性腫瘍を有する個体の処置のための、ｅｒｂ−２及びｅｒｂｂ−３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ−２標的化剤及び二重特異性抗体
JP2016182135A (ja) 抗ｈｅｒ２抗体および組成物
BR112013010764A2 (pt) composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição
BR112013010718A2 (pt) composição de anticorpo pan-her, composição farmacêutica, método para produção e uso da referida composição

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161207

Termination date: 20200303

CF01 Termination of patent right due to non-payment of annual fee